The INPPL1 Knockout HeLa Polyclonal Cells are a genetically engineered population derived from the human HeLa cell line, in which the INPPL1 gene has been disrupted using CRISPR/Cas9-mediated gene editing. Supplied as a polyclonal cell pool, this product contains heterogeneous INPPL1 knockout variants, enabling researchers to study the consequences of INPPL1 loss-of-function in a mixed cell population. This format is particularly suited for pooled screening, phenotypic analyses, and pathway interrogation where clonal homogeneity is not required.
The HeLa host cell line derives from a cervical adenocarcinoma and is stably positive for human papillomavirus type 18 (HPV18). As an immortalized epithelial model, HeLa cells are extensively employed in cancer research to investigate oncogenic transformation, signal transduction, and cytoskeletal organization, offering a relevant disease context for the study of cervical adenocarcinoma and general tumor cell biology.
The INPPL1 gene encodes a phosphoinositide 5-phosphatase that specifically hydrolyzes the 5-phosphate of PIP3 to generate PI(3,4)P2, counteracting the kinase activity of PI3K. Its activity is stimulated downstream of insulin, growth factors, and receptor tyrosine kinases, and it is recruited to signaling complexes by adaptors Cbl, Grb2, and Shc. By depleting PIP3, INPPL1 reduces Akt membrane recruitment and phosphorylation, thereby lowering the activity of downstream effectors including mTORC1, FoxO transcription factors, GSK3??, and the RabGAP AS160. Additionally, INPPL1 interacts with cytoskeletal regulators filamin and LIMK, integrating PIP3 signaling with actin filament dynamics.
In HeLa cells, the HPV18 E6 and E7 oncogenes constitutively enhance PI3K/Akt pathway activity and drive cytoskeletal reorganization. INPPL1 disruption in this background further elevates PIP3 levels, leading to hyperactivated Akt/mTOR signaling and dysregulated cell dynamics. This polyclonal model enables dissection of PIP3-dependent phenotypes such as enhanced proliferation, migration, and insulin sensitivity in the context of cervical adenocarcinoma. The loss of INPPL1??s interaction with filamin and LIMK may also amplify actin reorganization, providing a system to study cancer cell motility.
These polyclonal knockout cells support a variety of experimental approaches. Western blotting for phospho-Akt (Ser473) provides a direct readout of pathway hyperactivation. Immunofluorescence can localize PIP3 accumulation, while migration and proliferation assays quantify functional consequences. Co-immunoprecipitation allows mapping of disrupted INPPL1 protein interactions. Typical applications include modeling insulin resistance, screening SHIP2 inhibitors, and investigating actin remodeling in cancer. For further assistance, contact Ascent Research.
